Comparison of 2 New Real-time Polymerase Chain Reaction-Based Urinary Markers in the Follow-Up of Patients With Non -Muscle-Invasive Bladder Cancer
No Thumbnail Available
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Xpert Bladder Cancer Monitor un Bladder EpiCheck tests ir 2 jauni reāllaika polimerāzes ķēdes reakcijas urīna marķieri, kas izstrādāti urīna marķieru agrīnai recidivējoša urotelija vēža diagnostikai. Kopā šie divi testi atklāja aptuveni 92,11 % augstas pakāpes audzēju. To specifiskums bija augsts, bet nesasniedza izcilo citoloģijas vērtību. Negatīvā prognozējošā vērtība abiem testiem bija vienāda un augstāka nekā citoloģijai, jo īpaši, ja testus izmantoja kopā (92,24 %). Šie 2 jaunie testi ir daudzsološi kā urīna biomarķieri. Tos var izmantot kombinācijā, lai maksimāli palielinātu jutīgumu mazāk invazīvā veidā, tādējādi samazinot invazivitāti pacientu ar neinvazīvu urīnpūšļa vēzi novērošanā un samazinot diskomfortu pacientiem, kā arī komplikācijas un izmaksas.
The Xpert Bladder Cancer Monitor and Bladder EpiCheck test are 2 new real-time polymerase chain reaction-based urinary markers developed for the early diagnosis of recurrent urothelial cancer. Together, the 2 tests detected approximately 92.11% of high-grade tumors. Their specificity was high but could not reach the excellent value of cytology. The negative predictive value was the same for both tests and was higher than that for cytology, especially when the tests were used together (92.24%). These 2 new tests hold promise as urinary biomarkers. They may be used in combination to maximize sensitivity in a less invasive way, thereby reducing invasiveness in the follow-up of patients with non-muscle-invasive bladder cancer and decreasing discomfort for the patients as well as complications and costs.
The Xpert Bladder Cancer Monitor and Bladder EpiCheck test are 2 new real-time polymerase chain reaction-based urinary markers developed for the early diagnosis of recurrent urothelial cancer. Together, the 2 tests detected approximately 92.11% of high-grade tumors. Their specificity was high but could not reach the excellent value of cytology. The negative predictive value was the same for both tests and was higher than that for cytology, especially when the tests were used together (92.24%). These 2 new tests hold promise as urinary biomarkers. They may be used in combination to maximize sensitivity in a less invasive way, thereby reducing invasiveness in the follow-up of patients with non-muscle-invasive bladder cancer and decreasing discomfort for the patients as well as complications and costs.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
urīnpūšļa vēzis; citoloģija; novērošana; neinvazīvs urīnpūšļa vēzis; urīna marķieris, bladder cancer; cytology; follow-up; non–muscle-invasive bladder cancer; urinary marker